Literature DB >> 17979267

Specificity in molecular design: a physical framework for probing the determinants of binding specificity and promiscuity in a biological environment.

Mala L Radhakrishnan1, Bruce Tidor.   

Abstract

Binding specificity is an important consideration in drug design. An effective drug molecule often must bind with high specificity to its intended target in the body; lower specificity implies the possibility of significant binding to unintended partners, which could instigate deleterious side effects. However, if the target is a rapidly mutating agent, a drug that is too specific will quickly lose its efficacy by not binding well to functional mutants. Therefore, in molecular design, it is crucial to tailor the binding specificity of a drug to the problem at hand. In practice, specificity is often studied on a case-by-case basis, and it is difficult to create general understanding of the determinants of specificity from the union of such available cases. In this work, we undertook a comprehensive, general study of molecular binding with emphasis on understanding the determinants of specificity from a physical standpoint. By extending a theoretical framework grounded in continuum electrostatics and creating an abstracted lattice model that captures key physical aspects of binding interactions, we systematically explored the relationship between a molecule's physical characteristics and its binding specificity toward potential partners. The theory and simulated binding interactions suggested that charged molecules are more specific binders than their hydrophobic counterparts for several reasons. First, the biological spectrum of possible binding characteristics includes more partners that bind equally well to hydrophobic ligands than to charged ligands. Also, charged ligands, whose electrostatic potentials have strong orientational dependence, are more sensitive to shape complementarity than their hydrophobic counterparts. Ligand conformational and orientational flexibility can further influence a charged molecule's ability to bind specifically. Interestingly, we found that conformational flexibility can increase the specificity of polar and charged ligands, by allowing them to greatly lower the binding free energy to a select few partners relative to others. Additionally, factors such as a molecule's size and the ionic strength of the solution were found to predictably affect binding specificity. Taken together, these results, all of which stem from a unified theoretical framework, provide valuable physical insight into the general determinants of binding specificity and promiscuity in a biological environment. The general principles discussed here could prove useful in the design of molecules with tailored specificities, leading to more effective therapeutics.

Mesh:

Substances:

Year:  2007        PMID: 17979267      PMCID: PMC3465720          DOI: 10.1021/jp074285e

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  63 in total

Review 1.  Energy functions for protein design.

Authors:  D B Gordon; S A Marshall; S L Mayo
Journal:  Curr Opin Struct Biol       Date:  1999-08       Impact factor: 6.809

2.  Charge optimization of the interface between protein kinases and their ligands.

Authors:  Peter A Sims; Chung F Wong; J Andrew McCammon
Journal:  J Comput Chem       Date:  2004-08       Impact factor: 3.376

3.  Sensitivity Analysis and Charge-Optimization for Flexible Ligands:  Applicability to Lead Optimization.

Authors:  Michael K Gilson
Journal:  J Chem Theory Comput       Date:  2006-03       Impact factor: 6.006

Review 4.  Can we rationally design promiscuous drugs?

Authors:  Andrew L Hopkins; Jonathan S Mason; John P Overington
Journal:  Curr Opin Struct Biol       Date:  2006-01-25       Impact factor: 6.809

Review 5.  Protein kinase inhibition: different approaches to selective inhibitor design.

Authors:  Giovanna Scapin
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

6.  Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins.

Authors:  Maddalena Panigada; Tiziana Sturniolo; Giorgio Besozzi; Maria Giovanna Boccieri; Francesco Sinigaglia; Giuliana Gialdroni Grassi; Fabio Grassi
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 7.  A century-old debate on protein aggregation and neurodegeneration enters the clinic.

Authors:  Peter T Lansbury; Hilal A Lashuel
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

8.  Structural basis of carbohydrate recognition by lectin II from Ulex europaeus, a protein with a promiscuous carbohydrate-binding site.

Authors:  R Loris; H De Greve; M H Dao-Thi; J Messens; A Imberty; L Wyns
Journal:  J Mol Biol       Date:  2000-08-25       Impact factor: 5.469

9.  The specificity of cross-reactivity: promiscuous antibody binding involves specific hydrogen bonds rather than nonspecific hydrophobic stickiness.

Authors:  Leo C James; Dan S Tawfik
Journal:  Protein Sci       Date:  2003-10       Impact factor: 6.725

Review 10.  Molecular mimicry and immune-mediated diseases.

Authors:  M B Oldstone
Journal:  FASEB J       Date:  1998-10       Impact factor: 5.191

View more
  6 in total

Review 1.  Protein promiscuity and its implications for biotechnology.

Authors:  Irene Nobeli; Angelo D Favia; Janet M Thornton
Journal:  Nat Biotechnol       Date:  2009-02       Impact factor: 54.908

2.  How to Model for a Living: The CSGF as a Catalyst for Supermodels.

Authors:  M L Radhakrishnan
Journal:  Comput Sci Eng       Date:  2021-10-14       Impact factor: 2.152

3.  Targeting ligand-gated ion channels in neurology and psychiatry: is pharmacological promiscuity an obstacle or an opportunity?

Authors:  Matt T Bianchi; Emmanuel J Botzolakis
Journal:  BMC Pharmacol       Date:  2010-03-02

Review 4.  Rational approaches to improving selectivity in drug design.

Authors:  David J Huggins; Woody Sherman; Bruce Tidor
Journal:  J Med Chem       Date:  2012-01-12       Impact factor: 7.446

5.  Molecular mechanisms and design principles for promiscuous inhibitors to avoid drug resistance: lessons learned from HIV-1 protease inhibition.

Authors:  Yang Shen; Mala L Radhakrishnan; Bruce Tidor
Journal:  Proteins       Date:  2015-02

6.  Conjugates for use in peptide therapeutics: A systematic review and meta-analysis.

Authors:  Ashan Wijesinghe; Sarika Kumari; Valerie Booth
Journal:  PLoS One       Date:  2022-03-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.